Clinical trials of health information technology interventions intended for patient use: Unique issues and considerations by DeVito Dabbs, Annette et al.
Clinical Trials of Health IT Interventions Intended for Patient
Use: Unique Issues and Considerations
Annette DeVito Dabbs, PhD, RNa, Mi-Kyung Song, PhD, RNb, Brad Myers, PhDc, Robert P.
Hawkins, PhDd, Jill Aubrecht, MBA, MSN, RNa, Alex Begey, BSa, Mary Connolly, RN, BSNa,
Ruosha Li, PhDa, Joseph M. Pilewski, MDa, Christian A. Bermudez, MDa, and Mary Amanda
Dew, PhDa
aUniversity of Pittsburgh; Pittsburgh, Pennsylvania, USA
bUniversity of North Carolina, Chapel Hill; Chapel Hill, North Carolina, USA
cCarnegie Mellon University; Pittsburgh, Pennsylvania, USA
dUniversity of Wisconsin; Madison, Wisconsin, USA
Abstract
Background—Despite the proliferation of health information technology (IT) interventions,
descriptions of the unique considerations for conducting randomized trials of health IT
interventions intended for patient use are lacking.
Purpose—Our purpose is to evaluate Pocket PATH® (Personal Assistant for Tracking Health), a
novel health IT intervention, as an exemplar of how to address issues that may be unique to a
randomized controlled trial to evaluate health IT intended for patient use.
Methods—An overview of the study protocol is presented. Unique considerations for health IT
intervention trials and strategies to maintain equipoise, monitor data safety and intervention
fidelity, and keep pace with changing technology during such trials are described.
Lessons Learned—The sovereignty granted to technology, the rapid pace of changes in
technology, ubiquitous use in health care and obligation to maintain the safety of research
participants challenge researchers to address these issues in ways that maintain the integrity of
intervention trials designed to evaluate the impact of health IT interventions intended for patient
use.
Conclusions—Our experience evaluating the efficacy of Pocket PATH may provide practical
guidance to investigators about how to comply with established procedures for conducting
randomized controlled trials and include strategies to address the unique issues associated with the
evaluation of health IT for patient use.
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Health information technology (IT) represents one of the ‘transforming’ advancements that
impact the way patients manage their health information, communicate with healthcare
providers, and support the goal for patients to be informed, active participants in their health
care (1–3). The recent proliferation of health IT interventions intended for patient use and
the growing recognition of the importance of rigorous trials to evaluate such interventions
(4), revealed several substantial issues that can arise in such trials. A description of the
unique considerations for conducting randomized trials of health IT interventions intended
for patient use is therefore warranted and timely.
Maintaining equipoise
The ethical basis for medical research involving assignment of participants to different
interventions requires investigators to maintain equipoise during the conduct of the trial
(5,6). Equipoise refers to a state of genuine uncertainty regarding the comparative
therapeutic merits of different arms of an intervention trial (7). Evidence suggests that even
when consent forms include clear statements about equipoise, the majority of participants
remain unaware that the best intervention is in fact unknown (5, 8–10). Participants often
hold a preference for one intervention over another based on personal values and interest
(11, 12), suggesting that equipoise may not be fully understood (7).
While a full discourse of culture and technology is beyond the scope of this paper, it is in
this context that the issue of maintaining equipoise between technological and non-
technological interventions is situated (13) and is thus an important consideration for health
IT researchers. In our society, technology often is granted sovereignty (14). The success of
technology in providing convenience, comfort and speed has led our society to view non-
technological alternatives as naturally inferior. Technology often is equated with progress
and promise and, as such, implies that technology is better than traditional or conventional
approaches that are considered old-fashioned and outdated (14, 15). In trials where
participants are assigned randomly to different interventions, at least one of which is
technology-based, it is important to provide assurance that none of the participants,
including those randomized to a standard care control group, are being harmed by having a
chance at receiving an inferior therapy.
Monitoring data and safety
While investigators conducting research on human beings are obligated to guard the safety
and well being of study participants, data and safety monitoring (DSM) procedures may or
may not be required depending on the complexity or risks involved in the study. According
to the codes of ethics developed to address the obligations of researchers employing
electronic data collection and communication via the Internet and other health technologies,
(16–19) researchers need to establish procedures to monitor the health indicators collected
as outcome data of a health IT intervention so that worrisome condition changes are detected
and patient safety is ensured.
Maintaining intervention consistency amidst the changing pace of technology
A hallmark of intervention trials is achievement of internal validity of the intervention, (i.e.,
keeping the intervention constant over the course of a trial). Such consistency is necessary
for drawing accurate conclusions about the relationship between the intervention and the
effects that are examined in the study. However, achieving intervention consistency may be
particularly challenging in the case of health IT interventions when IT itself is an integral
part of the intervention, not merely a mode of intervention delivery. The speed of
technology development clearly outpaces the timeline required to develop and conduct a
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typical full-scale intervention trial (20). During the same study period, new technologies and
applications are constantly being developed and entering the technological landscape. New
developments may be problematic because the health IT interventions under study may rely
on technology platforms and applications that are either merely outdated, at best, or, at
worst, completely obsolete by the end of the trial period. Conversely, the inability to use the
newer technologies and hardware that become available during the trial is also problematic,
since the latest technologies are often simpler for designers to program and more intuitive
for users. Furthermore, new and independent technologies targeting the same health
outcomes may be introduced to the market and thus available to the participants during the
course of the study.
Riley and others (21–24) have suggested strategies for conducting trials of health IT
interventions in order to keep pace with technology development, including such strategies
as focusing on testing the core components of the health IT intervention rather than a
specific delivery platform, leveraging a variety of technologies to deliver the health IT
intervention during the trial, shortening follow-up periods to accommodate changes in
technology, evaluating proximate outcomes and model or simulated more distal outcomes,
or using alternative designs in order to identify combinations of intervention components
that optimize outcomes.
Monitoring intervention fidelity for health IT
The importance of customizing the intervention fidelity evaluation plan to the unique
components of each intervention has been established, as have the challenges associated
with evaluating fidelity of complex interventions (25). Because implementation of most
health IT interventions involves a dynamic interplay between the participant and a
technological application or interface and can vary at any stage of the process (delivery,
receipt, acceptance, and intention to use), models of intervention fidelity which focus
exclusively on intervention delivery are deemed inadequate for evaluating the fidelity of
health IT interventions. An assessment of human factors, such as receipt and acceptance
known to influence user adoption and intended behavior change (26–30) also should be
included in monitoring to ensure that the health IT intervention is implemented as planned.
We describe a randomized controlled trial (RCT) designed to evaluate the effects of Pocket
PATH® (Personal Assistant for Tracking Health), a novel health IT intervention to promote
self-care agency (the capability and willingness to engage actively in self-care behaviors),
the performance of self-care behaviors and ultimately transplant-related health outcomes
among patients with chronic illness to illustrate how we addressed the issues unique to trials
of health IT intended for patient use. Because our trial tests Pocket PATH in a specific
patient population (recipients of lung transplants), we also provide a brief overview of this
population and the relevance of health IT to it.
Methods
Health IT and lung transplantation
Barely 84% of lung transplant recipients (LTRs) survive the first year after transplantation,
and only 64% and 53% of LTRs are alive by 3 and 5 years, respectively (31). LTRs
experience more transplant-related complications, higher health resource utilization, and
higher mortality than recipients of other solid organs (32). Prevention and detection of early
complications is known to reduce the likelihood of future impairments in lung function and,
therefore, morbidity and mortality (33). However, no RCT has tested health IT interventions
designed to promote self-care and improve health after lung transplantation.
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The features of Pocket PATH were designed to support patients’ self-care agency and
performance of self-care behaviors, such as adhering to the medical regimen, performing
self-monitoring and communicating condition changes to clinicians after lung
transplantation. These behaviors are known to promote better health outcomes for persons
with a variety of chronic illnesses; thus health IT interventions designed to support self-care
behaviors among different patient populations are likely to include similar features although
the details of the regimens and particular health indicators may differ among types of
chronic illnesses. Therefore, the issues associated with conducting a RCT of Pocket PATH
are likely to be generalizable to other IT interventions with similar goals.
Pocket PATH provides the LTR a Smartphone with customized programs (see Figure 1) for
recording vital signs, symptoms and values from laboratory assays, graphical displays of
changes in those values over time, and automatic generation of feedback messages to
provide decision-support for LTRs about when and what to report to their transplant
providers (see Table 1).
Based on the success of Pocket PATH in promoting self-care and quality of life in the early
post-transplant period (34), a full–scale, RCT to compare the efficacy of Pocket PATH for
promoting self-care agency (the capability and willingness to engage in self-care behaviors),
self-care behaviors and hence improving transplant-related health during the first 12 months
after lung transplantation relative to standard care is nearing completion.
Design and setting
The Pocket PATH trial uses an RCT design with repeated-measures. The RCT is conducted
in association with University of Pittsburgh Medical Center Cardiothoracic Transplant
Program and is approved by the University of Pittsburgh Institutional Review Board.
Specific aims
The primary aims of the Pocket PATH trial are to: 1) compare the effects of Pocket PATH
versus standard care on self-care agency and self-care behaviors at 2, 6, and 12 months post-
discharge after lung transplantation, and 2) compare the effects of Pocket PATH versus
standard care on transplant-related health (post-transplant complications, re-hospitalizations,
and health related quality of life) at 2, 6, and 12 months post-discharge after lung
transplantation. A secondary aim of the study is to explore intervention fidelity, patient
acceptance and adoption of the Pocket PATH intervention to support the processes of self-
care after lung transplantation.
Sample
Eligible participants include adult LTRs who are recovering on the cardio-thoracic
transplant step-down unit prior to hospital discharge and are able to read and speak English.
LTRs excluded had received a prior organ transplant (to avoid experiential effects) or were
experiencing a condition that precluded discharge from the hospital or limited their ability to
be actively involved in their post-transplant care. The targeted sample size of 202 was set to
provide 80% power to detect an effect size of 0.45 (34) for the performance of self-care
behaviors at a two-tailed significance level of 0.05 using a t-test for independent samples.
After baseline measures were collected and discharge was imminent, recipients were
assigned randomly to either the Pocket PATH intervention group or the standard care
control group. Recruitment and randomization for the study were completed in December
2011 (see eFigure 1).
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Control group: Standard care—Standard preparation of LTRs for discharge and
transition to home included a one-on-one, educational session delivered by the transplant
nurse coordinator of the clinical team prior to hospital discharge. During the session, “Need
to Know” topics (e.g., self-monitoring and medication taking) were reviewed with each LTR
and typically a family caregiver(s). A home reference binder was provided to each recipient
that included paper-and-pencil “Log Sheets” and instructions to record daily health
indicators (e.g., pulse, blood pressure, temperature, spirometry, and symptoms). LTRs also
were given written instructions describing parameters for “when to call” the transplant team
if changes in these health indicators occurred. After discharge, a referral for at least one
home visit was arranged. All LTRs were scheduled to return to the transplant center for
routine follow-up evaluations within the first week, then monthly for the first three months,
at least quarterly for the first year, and more frequently as needed. The transplant nurse
documented the delivery of each component of the discharge educational session in the
recipient’s medical record.
Intervention Group: Pocket PATH intervention in addition to standard care—
The core components of the Pocket PATH intervention, goals and the corresponding
interventionist behaviors are shown in Table 2. Components included defining self-care
agency (i.e., what it means for patients actively to participate in their care), the importance
of performing recommended self-care behaviors and the role of Pocket PATH in promoting
higher levels of patient activation and self-care. LTRs also were provided the Pocket PATH
device and trained to use its features and custom programs, including return demonstrations
of competency using the device for self-monitoring, adhering to the regimen and decision-
support about reporting condition changes to the transplant providers. The training session
lasted approximately 30 minutes and was delivered by one of two trained study
interventionists. Following training, recipients were instructed to use the device and its
programs to track health indicators and to report changes in their conditions according to the
coordinator’s discharge instructions. Recipients were given a Pocket PATH User Support
Manual and a toll-free number to call for help with technical problems with the device that
was answered by research staff members during regular business hours. In the event that
recipients were not able to perform the tasks after training, remedial training was provided
on an individual basis. Because the device was intended to assist with self-care behaviors,
data recorded on it were logged and graphed for each recipient to view (see Figure 2). The
device was programmed to generate automatic decision support messages reminding
recipients to report changes to the transplant clinicians whenever health indicators reached
the threshold for reporting changes described in the standard discharge instructions. Data
were not shared directly with clinicians; instead the data were uploaded automatically to the
research project’s data base daily via secure, cellular connection.Throughout the training
session and subsequent contacts, trainers stressed to LTRs, both orally and in the training
materials, that the transplant team maintained responsibility for managing all clinical care
and that changes in clinical data should be reported to the transplant care providers.
Whenever an LTR contacted the research staff about a clinical issue, the research team
redirected him/her to a member of the clinical transplant team.
Measures
Outcome measures—Self-care behaviors (performing self-monitoring, adhering to the
regimen and communicating changes in clinical condition), and transplant-related health
outcomes (complications, re-hospitalizations, psychological distress, and health-related
quality of life) were assessed at 2 months, 6 months, and 12 months post-hospital discharge.
These intervals were selected because: a) they coincided with return visits for routine post-
transplant evaluations, b) we detected effects by 2 months post-intervention in the pilot RCT
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(30), c) studies have shown that patients’ orientation toward sharing responsibility with their
health care providers is malleable, with intervention effects seen as early as 8 weeks (35,
36), and d) variation in transplant-related health outcomes are evident as early as 6 weeks
post-transplant (36, 37). Patient characteristics that may account for variation in intervention
effects (socio-demographic characteristics, self-care agency, quality of relationship with
primary lay caregiver, and health locus of control beliefs) were assessed at baseline prior to
randomization.
Health IT measures—Four measures of technology acceptance (38, 39), based on
concepts of the Technology Acceptance Model (TAM), (40, 41) were assessed: Perceived
Ease of Use, Perceived Usefulness, Attitudes Toward Using, and Intention to Use the
Technology. The range of scores for the four technology acceptance measures is 1–7; lower
scores reflect higher levels of technology acceptance. Consistent with the developers’
recommendations, they were administered by a trained data collector (non-interventionist)
after the Pocket PATH intervention had been delivered and the LTR had demonstrated
receipt but before they had experience using Pocket PATH independently. Evidence that
these technology acceptance measures predict a substantial portion of the use and
acceptance of technologies abounds (42–48). The measures are standardized, reliable (38),
and valid (49) and have been used across different settings. The After Scenario
Questionnaire (ASQ), (50) a three-item, reliable and valid questionnaire of satisfaction with
training to use a technology, was administered by a trained data collector (non-
interventionist) after completion of the TAM scales. The ASQ assesses user satisfaction with
the ease of task completion, the amount of time it took to complete a task, and the adequacy
of support information (such as a user manual or help screens) during the training session.
Items are rated on a seven-point Likert-type, scale (1 = Strongly Agree, to 7 = Strongly
Disagree); lower scores reflect higher levels of satisfaction with technology training.
Technology adoption—Data were collected for utilization of Pocket PATH based on
time-stamped data uploaded from each device over the course of the study. Patterns of usage
were examined for changes over time. We limited this evaluation to data related to
participants’ technology acceptance and satisfaction with technology training for several
reasons: 1) satisfaction and acceptance were assessed early in the study period prior to
participants’ independent use of Pocket PATH, 2) final data regarding Pocket PATH
adoption and its impact on self-care and transplant-related health for the 12-month study
period for all participants is not yet available, 3) there is insufficient power to draw
conclusions about adoption and impact of Pocket PATH on self-care and health outcomes
until all participants have completed the trial, and 4) our purpose is to raise awareness of
issues and considerations for conducting trials of health IT intended for patient use.
Results
Participants’ scores for the measures of health IT demonstrated high levels of acceptance of
the device by those assigned to receive it and satisfaction with the Pocket PATH training
session (see Table 3). Scores close to 1 indicate greater acceptance (TAM) and greater
satisfaction with training (TAQ).
Lessons Learned
Maintaining equipoise between technology-based interventions and control
conditions—When the Pocket PATH trial was getting underway, both transplant clinicians
and potential study participants expressed preconceptions about the superiority of the health
IT intervention compared to standard care. Our research team employed several strategies to
promote equipoise throughout the Pocket PATH trial. We intentionally referred to the trial
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as The Study Comparing Methods for Tracking Health at Home when communicating with
the transplant clinicians, potential study participants, and the Institutional Review Board.
Terms such as Pocket PATH and references to Smartphone or technology were explicitly
omitted from the trial title, from conversations about the study, and on the consent form.
Because the nurses and other members of the transplant team served as liaisons to identify
LTRs who met the eligibility criteria, educational sessions about the study and the need to
maintain equipoise were provided to members of the clinical lung transplant surgical team;
informational flyers were posted in the staff lounges to increase awareness of the study and
the need for equipoise. The consent materials included explicit statements regarding the
uncertainty of intervention benefits and, hence, the need to conduct the trial. Whenever a
LTR or clinician expressed an opinion about the superiority of the Pocket PATH
intervention, he/she was reminded that the integrity of the trial depended on suspending
beliefs about the superiority of technology.
Employing appropriate safety monitoring procedures—Data from the Pocket
PATH devices were uploaded automatically to the project Web site in order to track
patients’ utilization of the device and its features, but these data were not shared
automatically with the treating clinicians. We considered it our responsibility to monitor
data that may have indicated an unsafe change a patient’s clinical condition and outlined
steps for handling worrisome values. If during the process of monitoring participants’ use of
Pocket PATH the research team became aware of worrisome values, these data could not be
ignored. We developed a protocol for the research team to follow when critical values were
uploaded to ensure participant safety while keeping threats to study integrity to a minimum.
The aim was to follow a series of steps from the least to most intrusive to ensure that the
patient was safe (e.g., reviewing the electronic medical record to see whether a critical value
had been entered erroneously or the values had returned to normal) before resorting to
contacting the patient or clinical team directly to avoid influencing the outcomes of interest.
Since the purpose of the trial was to determine the impact of technology-enabled
interventions on self-care and thus patient outcomes, the protocol specified that only if the
more conservative actions were ineffective and the project staff judged the threat to be
critical would a clinical provider be notified. If such an intervention were necessary, it
would be duly recorded for analysis purposes. While it was important to include clinician
notification in the protocol, in the end, this step was not necessary during the entire Pocket
PATH trial.
In studies such as this one, unexpected risks may be detected more readily when the
responsibility for safety monitoring rests with a single member of the research team who can
perform close monitoring of individual participant data; therefore the project director who
had the clinical experience to detect unanticipated changes in participant conditions was
responsible for: a) reviewing uploaded data every 72 hours to ensure that changes were
detected in a timely manner and 2) following the established protocol for handling any
critical values. Our monitoring plan also included a mechanism for objective review and
oversight of the process. On a quarterly basis, de-identified data were reviewed by a clinical
expert in lung transplantation who assessed whether all critical values had been detected and
handled appropriately according to our protocol. The expert also was poised to review the
impact of notifying clinicians of critical values had this final protocol-defined action been
warranted. A full description of our monitoring plan and recommendations for developing
monitoring procedures for other trials involving health IT have been published (51). The
monitoring strategies included risk-monitoring procedures, automatic surveillance to detect
critical values and procedures for timely and appropriate action to ensure participant safety
(52). Data recorded by participants in the standard care group were not available to the
research team until participants shared their health logs with their transplant clinicians
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during their regularly scheduled return clinic visits to the transplant center which coincided
with our data assessment time points.
Maintaining intervention consistency amidst the changing pace of technology
—Some health IT trials may be better able than others to maintain intervention consistency
while keeping pace with technological developments; the trial of the Pocket PATH
intervention exemplifies strategies for dealing with changes beyond the control of the trial
designers. The Pocket PATH software originally was developed for the iPAQ [HP iPAQ
hx2755 Pocket PC; Hewlett Packard; Windows mobile V. 2003 SE]. Although at the time
the iPAQ was among the most versatile pocket personal computers, it relied on modem
connectivity to upload data remotely. By the time the RCT was ready to begin, cellular
connectivity became available so we abandoned the iPAQ in favor of a Smartphone. We
decided to provide LTR Smartphones (e.g., Tilt, HTC, Windows Mobile Professional 6)
loaded with the Pocket PATH programs. To avoid having to re-write the graphic user
interface programs, our choices were limited to phones that used Windows Mobile with
similar screen dimensions. As new versions of.NET and OpenNETCF (the frameworks used
for developing the programs) were released, we migrated to the newer versions because they
added more features and simpler ways of doing things but also because the older versions no
longer were supported. Migrations almost always led to compatibility problems with what
we had already built, thus requiring adjustments to the source code. Each migration required
testing to ensure Pocket PATH worked as well for users as before the changes.
Ultimately, as often occurs, as new device models were introduced, the older Tilt models
were no longer available for purchase, so we had to change models [Pure, HTC, Windows
Mobile Professional 6.5]. Migrating from iPAQ to Smartphones presented challenges,
especially to adapt the graphing functionality to work with any screen resolution. However,
since the Tilt and Pure phones used different versions of Windows Mobile than the iPAQ, to
keep the user interface and features consistent, our software engineer had to ensure that the
Pocket PATH programs worked seamlessly across different versions of Windows Mobile.
Even upgrading from version 6 to 6.5 caused problems as some things were not backwards
compatible. Uploading mechanisms had to be modified between the Tilt and Pure versions
because v6.5 of Windows Mobile added certain restrictions to internet connectivity from
within applications. Additionally, while we were able to maintain consistency with our
original intervention, every time we were forced to switch to a different mobile device we
had to update our training manuals and educational materials to match the newer model,
adding cost and effort to an already expensive intervention trial. After changing platforms
three times, we purchased enough Pure models to complete the study rather than having to
change phone platforms again.
In spite of essential modifications, we believe we were able to maintain consistency in the
user-interface and functionality so that each LTR in the intervention arm had a comparable
experience with Pocket PATH. However, some health IT interventions may be linked
inextricably to certain technologies, applications or interfaces and less able to be modified to
keep pace with newly introduced technologies and applications. Depending on the health IT
intervention under study, investigators may be forced to maintain intervention consistency
over the course of the trial at the risk of evaluating an intervention that is outdated and
possibly obsolete by the end of the trial.
Maintaining intervention fidelity for health IT interventions—A variety of models
of intervention fidelity exist, but we adopted the following definition: the degree to which
the intervention implementation process is an effective realization of the intervention as
planned (53). We developed an intervention fidelity framework to guide the development of
a multi-component plan to evaluate intervention fidelity for the Pocket PATH trial. A full
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description of the components of the framework, how each is measured and how the data
regarding fidelity is used to test the relationships purported in the model and to draw
conclusions about the consistency, validity, and effectiveness of the Pocket PATH
intervention have been published (54). The concepts included in the model of intervention
fidelity for health IT interventions go beyond delivery (the extent to which the intervention
is delivered as intended) and receipt (the extent to which the intervention is received as
intended) to include the concept of technology acceptance (the extent to which the subject
has positive perceptions, attitudes, and intention to use the intervention). Although these
concepts are believed to apply to fidelity of all health IT interventions, the information that
is monitored and the types of data available are intervention specific (34, 35, 45). We
believe that this multi-dimensional view of intervention fidelity allows for a better
understanding of the role that technology acceptance plays in the adoption of health IT
interventions and thus enactment of the behaviors the interventions are intended to promote.
Discussion and Conclusion
In this study we used a novel health IT application to maximize the contribution of LTRs
themselves in preventing and detecting post-transplant complications. Health IT
interventions may be particularly appropriate for organ-transplant recipients because most
live outside the local region of the transplant center and no other personal computer support
is required in the home. All LTRs were expected to perform the self-care activities
supported by Pocket PATH; ratings of technology acceptance by participants in the IT
intervention arm were high, but it is as yet unknown whether the use of this health IT device
will prove to be superior to standard care in promoting self-care behaviors and transplant-
related health outcomes. Data analysis of the trial outcome measures was underway at the
time of acceptance of this paper for publication.
The protocol to evaluate the efficacy of Pocket PATH provides practical guidance to
investigators who wish to evaluate other health IT interventions, particularly those designed
to promote self-care behaviors among patients with other chronic illness. Issues of
compliance with established procedures for conducting RCTs and strategies to address the
issues uniquely associated with the evaluation of health IT intended for patient use in the
Pocket PATH trial included maintaining equipoise (i.e. uncertainty regarding the outcome of
the study), ensuring an appropriate level of safety monitoring surveillance, ensuring the
validity and integrity of trial data, customizing the plan for monitoring intervention fidelity
(i.e., including all potentially variable aspects of intervention fidelity, including delivery,
receipt, acceptance, and intention to use), and adopting strategies to keep pace with
technology change.
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Flow Diagram of Recruitment and Randomization in the Pocket PATH Trial
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Selected Screen Shots of the Pocket PATH® Graphic User Interface
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Table 1
Features of Pocket PATH® Intervention to Support Self-Care Behaviors
Features to Support Self-Monitoring
• Direct data entry (vital signs, symptoms, lab values)
• Data display options (log and graphs)
• Critical values indicated on graphs




Features to Support Communicating with Transplant Team
• Automatic feedback messages generated when critical values are entered
• Log of all previously generated feedback messages
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Table 2
Core Components, Measurable Goals and Interventionists’ Behaviors
Core Component
Goal Interventionists’ Behaviors
I. Introduction & Preparation
Goal: patient at ease and prepared for learning
I a) Introduce self and session
I b) Acknowledge the challenges of performing self-care after
transplantation
I c) Assess barriers to performing self-care (medication timing,
effects, symptoms, motor skills)
II. Discussion of Activation & Self-Care
Goal: patient understands the importance of being an activated
patient and performing recommended self- care activities
Ii a) Define an activated patient (one who performs self-care and
is an active partner with transplant providers)
Ii b) Define self-care activities: (self-monitor, follow regimen,
notify coordinator of changes)
Ii c) Explain importance of being an active partner and
performing self-care activities
III. Explanation of Pocket PATH
Goal: patient understands the role of technology in promoting
higher levels of patient activation
iii) Explain the importance of balancing use of technology
(Pocket PATH) with human factors of technology
acceptance
IV: Demonstration
Goal: patient engages in hands-on practice using Pocket PATH
features
iv a) Review personal interpretation of events as the primary
source of information; technology only secondary
iv b) Introduce device, user training manual
iv c) Introduce features of Pocket PATH and link to care
expectations regarding self-care
iv d) Demonstrate features
iv e) Observe patient return demonstration of features
V. Evaluation of patient competence
Goal: patient demonstrates competence in using Pocket PATH
features and draws linkages between use and improved patient
activation and self-care
v a) Evaluate competence of patient using Pocket PATH
v b) Self-monitoring (entering, viewing and interpreting data)
v c) Adhering (using reminders and calendars)
v d) Communicating condition changes appropriately (based on
automatic decision-support feedback messages)
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Table 3
Mean and Standard Deviation for Health IT Measures (TAM and ASQ), IT Intervention Arm Only
Technology Acceptance Model (TAM) Mean Score Standard Deviation
 Perceived Ease of Use 1.44 .67
 Perceived Usefulness 1.40 .57
 Attitudes Toward Using Technology 1.34 .53
 Intention to Use the technology 1.28 .80
After Scenario Questionnaire (ASQ)** 1.25 .52
*
N=65; TAM measures were added to the battery of instruments after the start of study. Possible scores for the TAM measures ranged from 1–7
with lower scores indicating greater acceptance.
**
N=93; 6 participants did not complete the ASQ. Scoring was based on a 7-point scale; lower scores indicate greater satisfaction.
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